DCAT Announces Board Leadership for FY 2021-22

Robbinsville, New Jersey October 20, 2021 — The Drug, Chemical & Associated Technologies Association is pleased to announce the members of the Board of Directors for its upcoming fiscal year, November 1, 2021 to October 31, 2022. The members were interviewed and selected by the organization’s Leadership Development Committee and were approved by each Member Company’s official Delegate through balloting over the last several weeks.

Elected as President is Kerri McCullough Wood of Teva API, Teva Pharmaceuticals. Previously she served in the three Vice President positions. Joining Ms. McCullough on the Executive Committee will be Sally Macaluso of Johnson and Johnson, who previously served as Second Vice President/Finance Officer and Third Vice President. Ms. Macaluso will now become the First Vice President. Charles Davies of Merck & Co. Inc. previously served as Third Vice President and will now serve as the Second Vice President/Finance Officer. Elected to the Executive Committee as the new Third Vice President is Donna Gruol, XGen Pharmaceuticals DJB. Ms. Gruol has previously served as a member of DCAT’s Advisory Council, Leadership Development Committee, Alliance for Industry Women Committee, and as Chairperson of the Member Advantage Committee.

Re-elected as Directors on the Board are Lori Hoffman of Piramal Critical Care, Gavin Murdoch of Thermo Fisher Scientific, and Scott Price of Ren-Pharm International. Newly elected as Directors for a one-year term are Craig Douglas of Siegfried-USA and Courtney Stanton of Smithfield BioScience.

Immediate Past Presidents Sean Diver of Lonza AG and Paolo Magri of Bioseutica will round out the eleven-person Board of Directors. Visit https://dcat.org/board/ to view the Board of Directors.

About DCAT

The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing. With over 400 corporate members, DCAT is headquartered in Robbinsville, New Jersey.

Carol Lee
DCAT Executive Director